Carnot is an engineering company that is developing biofuel and hydrogen-powered Carnot engines with the aim of reducing global CO2 levels by 13%. The company asserts that metal engines, unable to withstand fuel combustion temperatures, waste one-third of fuel energy to cooling & have operating efficiencies of only 30%. Carnot argues that its engines can bring operating efficiencies up to 70%, halving fuel costs. It also intends to develop clean, secure, and affordable global off-grid energy solutions and provide disruptive technologies that are both commercially viable and environmentally friendly. Carnot was awarded a £157,000 Innovate UK Grant to develop an energy access solution in Sub-Saharan Africa. It was also awarded a place on OGTC Tech X accelerator, in partnership with organisations like British Petrol (BP), Equinor, and KPMG with a £100,000 funding. The company will use the investment to bump up the maximum theoretical engine efficiency to ~85%.
days to go:
Expired
investment:
£307,911
During their stay in hospital, around 7-10% of patients attract unexpected infections. In some cases, this is caused by unclean complex surgical tools. Aspetium have developed ultrasonic washers (dubbed "uSonic") to thoroughly decontaminate expensive surgical instruments, which can be safely reused to potentially prevent easily avoidable infections.
days to go:
Expired
investment:
£151,167
Using AI technology to help the elderly feel safer and more comfortable in their homes. miicare has developed wearable devices and wireless sensors to monitor body vitals. If any irregularity occurs a call will be placed to a family member, a social worker, or a 24/7 professional telecare service. This increases support for the elderly and peace of mind knowing an emergency can be easily and quickly addressed. All data is secured using blockchain encryption.
days to go:
Expired
investment:
£321,920
Aerobit is a smart inhaler, a tool for tracking medication use that records each time inhalers are taken and comes in a variety of cool toy designs. Built in sensors can even tell if the inhaler has been shaken correctly.
days to go:
Expired
investment:
£116,960
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go:
Expired
investment:
Withheld
Care Oncology Clinic is changing the face of cancer treatment by developing combinations of medicines to be taken alongside existing treatments such as radiotherapy, chemotherapy, hormone therapy and immunotherapy.
days to go:
Expired
investment:
£145,038
Aiming to prevent further deterioration and leakage of water and sewerage pipes, Aqualiner has developed their Melt in Place Pipe (MIPP). This patented technology consists of a sock insertion, which when heated, expands and melts onto the inner pipe and forms a solid glass-reinforced thermoplastic layer. This process can increase the longevity of existing pipes and is the only product of this type to be approved to be safe-for-use in drinking water pipes. The UK has more than 251,000 miles of water pipes, where almost 75,000 miles of pipes are classed as damaged.
Aqualiner firstly plans to sell the initial equipment in return for a small profit margin, but the materials and consumables used in the process will be sold to the licensed contractor directly as a second income stream. The third source of revenue is derived from fees charged to International territorial licensors for any Aqualiner sales.
The product has been developed with support from Anglian Water, Severn Trent Water and Yorkshire Water and is approved to be installed in US drinking water pipes.
days to go:
Expired
investment:
£642,471
Greenwall Environmental Group is a company engaged in making devices that can minimise non-biodegradable waste. It argues that asbestos remains the largest occupational killer in the UK today. Its product, Asbestosprobe, aims to change this situation. The company asserts that Asbestoprobe is arguably the world's first handheld analyser specifically designed to detect asbestos in real-time. It argues that current methods of detecting and recording the presence of asbestos are costly, invasive and slow. Asbestoprobe uses a point-and-click approach utilising NIR Spectroscopy and Artificial Intelligence (AI) to analyse the presence of asbestos in two minutes via the Asbestoprobe App. Greenwall plans to provide an annual software licensing model which grows through recurring revenue year on year. It endeavours to be a segment leader in the projected $1 billion global asbestos management market. The company will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£253,017
An engineering parts washing company using environmentally friendly aqueous solvent technology to clean components. As of January 2018, Safe Solvents uses a service model to generate income. The company has currently signed 131 contracts with businesses in the engineering sector and is expecting to sign almost 20 more by the end of their financial year in February 2019.
Safe Solvents has patented their technology and is aiming to achieve an 8% market share within the next 5 years in the UK. The company is now raising funds to expand further in the UK, as well as enter the global market. In addition, Safe Solvents is currently developing 4 new products with many more in the pipeline and the company is also seeking to enter other industries that can benefit from the technology.
days to go:
Expired
investment:
£1,158,520
Active Needle Technology offers an award-winning "needle actuating device" which has high value medical and consumer applications. The company's patent-pending proprietary ultrasonic technology enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others. The company aims to commercialise its technology into a $4+ billion special purpose needle market. After identifying obvious commercial advantages in the tattoo market, Active Needle plans to use its ultrasonic needle technology to develop a low-pain tattooing system. Moreover, the company has won an Innovate UK grant to develop and test the tattoo device. With the proceeds, the company will complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.
days to go:
Expired
investment:
£194,100
